Publication at First Faculty of Medicine, Third Faculty of Medicine |
2017
Abstract
Edoxaban belongs to the group of oral oral anticoagulants and is now the fourth in the series. Like others, it has the advantages of this group: fast onset of action, fixed anticoagulation effect at recommended doses, which need not be routinely monitored.
Edoxaban is approved for use on the basis of EMGAGE AF-TIMI 48 and HOKUSAI-VTE in the prevention of stroke in patients with atrial fibrillation of non-valvular etiology and for the treatment of venous thromboembolic disease. The recommended daily dose in both cases is 60 mg once a day to reduce to 30 mg if the creatinine clearance (15-50 ml / min.) or a body weight below 60 kg or at the same time as strong glycoprotein P inhibitors are reduced.